JULY 27: PUB MED: A trial involving men with hormone-refractory (advanced) prostate cancer who were treated with Provenge (a cellular immunotherapy product called Sipuleucel-T) had a “survival benefit” and only modest side effects, say the Washington researchers. READ MORE>
The integrated results…demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo.
The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
The most common adverse events associated with treatment were chills, pyrexia (fever), headache, asthenia (physical weakness), dyspnea (shortness of breath), vomiting, and tremor.